<DOC>
	<DOC>NCT00089791</DOC>
	<brief_summary>This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.</brief_summary>
	<brief_title>A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Women who are 60 to 90 years of age may be eligible to participate Bone mineral density (BMD) TScore at hip or spine must be less than 2.5 BMD TScore at the hip or the spine of less than 4.0 Patients with any severe or more than two moderate vertebral fractures on spinal xray at entry</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Postmenopausal Osteoporosis</keyword>
</DOC>